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Recently, positron emission tomography/computed tomography (PET/CT) has 
been introduced in the staging of oesophageal cancer. The impact of PET/CT 
fusion in comparison to side-by-side PET/CT in these tumours, was analyzed.  
Patients and Methods 
In 61 patients, 18-F-fluorodeoxyglucose (FDG)-PET and multidetector (md)-CT 
were performed within a two week interval. Software-fusion of md-CT and FDG-
PET was correlated with side-by-side FDG-PET/CT reading by two independent 
investigators. The gold standard was the pathological outcome or clinical 
evidence of progression during the first year of follow-up. 
Results 
In 18 patients (18/61; 30%), nodal staging improved with software-fusion. The 
number of nodal metastases increased in five patients and decreased in four 
patients, leading to up-staging in one patient (2%) and down-staging in three 
patients (5%). In nine cases (15%), certainty and localization of metastases 
improved. However, the number of distant metastases did not change and 
software-fusion did not have an influence on resectability.  
Conclusion 
PET/CT fusion substantially improves detection and localization of nodal 
metastases and may have an impact on locoregional treatment options. 




In cancer of the oesophagus and gastro-oesophageal junction (GOJ) curatively 
intended resection, eventually with neoadjuvant chemoradiation, is the most 
effective treatment option.1 As cure is only possible in the absence of distant 
metastases or local invasion into vital surrounding structures, optimal staging 
is indispensable for adequate preoperative patient selection preventing 
unnecessary surgical exploration.  
Endoscopic ultrasonography (EUS) in combination with fine needle aspiration 
(FNA), multidetector computed tomography (md-CT), and ultrasound (US) of 
the cervical region are commonly used staging methods.2 EUS-FNA is the most 
accurate in detecting nodal involvement and gross mediastinal invasion, 
whereas CT is the best imaging technique in detecting distant metastases.3 In 
the last decade, positron emission tomography with 18-F-fluorodeoxyglucose 
(FDG-PET) has become a frequently used staging technique.4-7 FDG-PET is 
especially applied for the detection of regional lymph node and distant 
metastases not visible on CT or EUS. Hence, pre-therapeutic FDG-PET alters 
assessment of the tumour stage in 15-22% of the patients.8-12 
Despite the improvements in preoperative staging, it is still difficult to determine 
resectability accurately. Depending on the pre-operative work-up, local invasion and 
distant metastases are found in 10-60% of patients during exploration.13-20 A 
combination of PET/CT images is thought to increase significantly the accuracy of 
staging because it correlates functional PET information with high resolution 
anatomical CT results.21-26 Previously, it was common practice to correlate FDG-PET 
with CT visually, but recently hybrid PET/CT or PET/CT fusion have gained more 
support. In this study the accuracy of PET/CT fusion in staging patients with cancer 
of the oesophagus or GOJ was evaluated and compared with visual correlation of 
PET and md-CT.  
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Patients and Methods 
Patient characteristics  
Retrospectively the medical records of 85 patients, who were staged by FDG-PET 
and md-CT and treated for cancer of the oesophagus or GOJ between January 2001 
and November 2004 were analyzed. Exclusion criteria were, treatment with 
neoadjuvant chemoradiation or a history of other malignancies. Twenty-four 
patients were excluded, either because the CT data from rural hospitals were 
missing (n=10) or the CT-slices were too thick (n=14). All the other patients were 
staged with EUS, 16-64 md-CT with slices of at least three mm and FDG-PET 
within two weeks of the time of presentation. In these 61 patients, it was feasible to 
perform a software-based PET/CT fusion. The mean age was 63.4 (SD±8.0; range 48-
80) years (Table 1). Fifty patients (82%) presented with an adenocarcinoma of the 
oesophagus. Most of the tumours (87%) were localized in the distal part of the 
oesophagus (n=40) or at the GOJ (n=13). Depending on tumour invasion and lymph 
node involvement, the tumours were divided into stage I-IV according to the 
tumour-node-metastasis (TMN) staging system of the Union Internationale Contre 
Le Cancer (UICC).27  
 
Computed tomography  
Multidetector row CT imaging was performed with a 16-64 md-CT scanner 
(Somatom Sensation, Siemens Medical Systems, Erlangen, Germany). The CT scans 
(collimation 16 x 1.5 mm) were performed from the neck to the upper abdomen with 
both intravenous and oral contrast. The reconstructed slices had a thickness of 3 
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Table 1. Patient characteristics 
Characteristics N   (%) 
Gender  
Male 51 (83.6) 
Female 10 (16.4) 
Age (years)  
Median (Range) 63.4 (48-80) 
Histology  
Adenocarcinoma 50 (82.0) 
Squamous cell carcinoma 11 (18.0) 
Localization  
High 8   (13.1) 
Low 40 (65.6) 
GOJ 13 (21.3) 
Clinical staging   
Stage I (T1N0M0)  4   (6.6) 
Stage II (T2-3N0M0/T1-2N1M0)  18 (29.5) 
Stage III (T3N1M0/T4N0-1M0) 32 (52.5) 
Stage IV (T1-4N0-1M1) 7   (13.7) 
Total 61 
Clinical stage: staging without software based FDG-PET/CT, GOJ:  
gastro-oesophageal junction 
 
Positron emission tomography with 18-fluorodeoxyglucose  
FDG-PET was performed with an ECAT HR+ positron camera (Siemens/CTI, 
Knoxville, TN, USA) acquiring 63 planes over a 15.8 cm axial field-of-view with 
retractable septa that enable 2D or fully-3D data acquisition. All patients fasted 
for at least 4 hours before 400 - 580 MBq FDG (depending on body weight) was 
administered intravenously. The transmission scans were performed for 3 
minutes per bed position allowing attenuation correction. The scans were 
corrected for decay, scatter and randoms, whilst the ordered subset expected 
maximization with two iterations and 16 subsets was used for reconstruction. A 
Gaussian filter of 5 mm full width at half maximum was used for post-
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smoothing of the reconstructed images.28 Data acquisition started in whole body 
mode 90 minutes after injection, for 5 minutes per bed position from the crown 
to the mid-femur. 
Diagnostic evaluation of CT and PET findings  
The images of the md-CT, EUS and FDG-PET techniques were reviewed 
independently by two experienced nuclear physicians. Round hypo-dense lymph 
nodes larger than 5 mm and lymph nodes measuring 10 mm or more on CT were 
determined to be pathological. Pathological lymph nodes at the celiac axis were 
classified as M1a metastases in the case of distal oesophageal cancer or as M1b 
metastases in the mid or proximal tumours. Cervical metastases were classified as 
M1a in the case of proximal cancer and as M1b for mid or distal tumours. The FDG-
uptake was scored on a four-point intensity scale: ‘normal’ (physiological), ‘slightly 
increased’, ‘moderately increased’ and ‘intensely increased’. These lesions were 
interpreted as: ‘absolutely benign’, ‘probably benign’, ‘indeterminate’, ‘probably 
malignant’ and ‘definitely malignant’. All the ‘indeterminate’, ‘probably malignant’ 
and ‘definitely malignant’ lesions were identified as hotspots. Suspect lesions were 
occasionally confirmed by FNA cytology, by pathological examination during or after 
surgery, or by radiological and clinical follow-up of at least one year. The lymph 
nodes were defined according to the Naruke lymph node stations (Table 2). 
 
PET/CT fusion compared with side-by-side PET/CT reading  
Together with an experienced radiologist all the reviewed FDG-PET and CT results 
were visually correlated (side-by-side) and scored by the same nuclear medicine 
physicians. Lymph nodes >1 cm on CT imaging without FDG-uptake on PET 
imaging, were scored as negative on visually correlated FDG-PET/CT staging. The  
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Table 2. Locoregional and distant lymph node stations according to Naruke 
Stat. Name Location 
1 Supraclavicular  Above suprasternal  notch and clavicles 
2R Right upper paratracheal Between intersection of caudal margin of innominate 
artery with trachea and the apex  of the lung 
2L Left upper paratracheal  Between top of aortic arch and apex of the lung 
3P Posterior mediastinal Upper para-oesophageal nodes, above tracheal 
bifurcation  
4R Right lower paratracheal 
nodes 
Between intersection of caudal margin of innominate 
artery with trachea and cephalic border of azygos 
vein 
4L Left lower paratracheal Between top of aortic arch and carina 
5 Aorto-pulmonary Subaortic and para-aortic nodes lateral to the 
ligamentum arteriosum 
6 Anterior mediastinal  Anterior  to ascending aorta or innominate artery 
7 Subcarinal Caudal to the carina of the trachea 
8 Para-oesophageal  From the tracheal bifurcation to the diaphragm 
9 Pulmonary ligament Within the inferior pulmonary ligament 
10R Right tracheobronchial From cephalic border of azygos vein to origin of RUL 
bronchus  
10L Right tracheobronchial Between carina and LUL branches 
15 Diaphragmatic Lying on the dome of the diaphragm, and adjacent to 
or behind its crura 
16 Paracardial Immediately adjacent to the gastro-oesophageal 
junction 
17 Left gastric Along the course of the left gastric artery 
18 Common hepatic Along the course of the common hepatic artery 
19 Splenic Along the course of the splenic artery 
20 Celiac At the base of the celiac artery 
Stat.: station, L: left, R: right, RUL: right upper lobe, LUL: left upper lobe 
 
rigid software-based PET/CT fusion was accomplished on a Siemens Leonardo 
Workstation using the Syngo 3D Fusion program. Fusion was carried out and 
PET/CT images were scored by the same experienced nuclear physician and 
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radiologist. Disagreement was resolved in a consensus meeting. The outcomes of 
software fusion were compared with visually correlated PET/CT and the differences 
between these two methods were scored as shown in Table 3. 
Enlarged lymph nodes > 1 cm on CT with negative PET findings were defined as 
negative. In the cases where fusion detected nodes that were initially not seen at all 
on md-CT or seen but not classified as physiological lymph nodes, these PET 
positive nodes were retrospectively defined as positive lymph nodes.  
The grade of certainty increased (outcome 2), when: the lymph nodes were detected 
retrospectively at the anatomic location of FDG-accumulation; the lymph nodes with 
a moderate suspect diameter or appearance turned out to be PET positive; the nodes 
at fusion were defined at another anatomical location than that seen by side-by-side 
review, but within the same TNM stage  or when fusion revealed FDG accumulation 
in a suspicious node located in the proximity of the primary tumour which was 
unclear for PET positivity on side-by-side correlation .     
 
Table 3. Improvements of software based FDG-PET/CT fusion compared with visual 
side-by-side correlation 
 Outcomes N=61 (%) 
1 No improvement 43 (70) 
2 Staging unaltered, increased certainty of suspicion or location 9 (15) 
3 Staging unaltered, number of metastases increased 4   (7) 
4 Staging unaltered, number of metastases decreased 1   (2) 
5 Staging unaltered, localization altered 0   (0) 
6 Upstaging, not leading to changes in resectability 1   (2) 
7 Upstaging, change in resectability from resectable to irresectable 0   (0) 
8 Downstaging, not leading to changes in resectability 3   (5) 
9 Downstaging, change in respectability from irresectable to resectable        0   (0) 
 
Follow-up  
The follow-up data of all the patients were available. The patients were followed 
according to a standardized programme consisting of an examination at the 
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outpatient department every three months for the first two years and every six 
months thereafter for a total period of five years. 
 
Statistical analysis  
Sensitivity, specificity and accuracy were calculated for both visual correlation and 
PET/CT fusion. Both the techniques were compared in nonparametric paired 








In 18 patients (30%), an improvement in the detection of locoregional and/or distant 
lymph node metastases was observed on fused PET/CT compared to visually 
correlated CT and PET (Table 3). Details of these 18 patients are summarized in 
Table 4.  
 
Increased certainty of localization and number of metastases  
In patients 1 to 9, the certainty of suspicious lymph nodes increased on PET/CT 
fusion without altering the clinical nodal staging. In patients 1 and 2, enlarged 
nodes were seen on md-CT in the paracardial region (patient 1) and near the left 
gastric artery (patient 2). On side-by-side correlation it was not possible to 
distinguish whether these nodes were PET positive or not, but fusion revealed FDG-
uptake in these nodes. In one patient (3), the lymph nodes were visible on CT at 
Naruke 4/5 and 17 without FDG accumulation on primary PET review. However, 
FDG-uptake was noted in two nodes after correction for the difference in height of 
the diaphragm vault. Only two nodes (Naruke 4/5 and 20) were eventually 
submitted for pathological examination as resection was abandoned because of 
tumour invasion in the pericardium (T4 stage). In patient 4, two nodes both > 1 cm 
(mean 1.6 x 1.1 ) at Naruke 16, did not show any FDG uptake, indicating a benign 
enlargement. Fusion revealed that there was indeed nodal FDG-uptake but that it 
was assimilated by FDG accumulation from the primary tumour. In patient 5, local 
and distant lymph nodes were detected by CT, as well as skeletal and lung 
metastases by PET. With precise anatomical correlation, PET/CT fusion could 
identify exactly the Naruke stations that were involved. Cytological proof was taken 
only from Naruke 18 and the six month clinical/radiological follow-up was taken as 
validation. In patients 7 and 8 a small paracardial (patient 6) and para-oesophageal 
node (patients 7) was missed on CT, although these lesions were suspected on PET 
and EUS. In patients 8 and 9, PET, CT and EUS did not agree on the localization of 
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suspected lymph nodes. PET/CT fusion enabled accurate identification and 
localization in the four nodes. 
 
Number of metastases altered, stage unaltered  
In four patients (10 to 13), the total number of nodal metastases increased as more 
pathological lymph nodes were observed on PET/CT fusion, though the TNM stage 
remained unaltered. In patient 10, PET/CT fusion revealed lymph node metastases 
close to the tumour (Naruke 8 and 16) which were not suspect on CT and were 
thought to be primary tumour tissue at first PET diagnosis. In patient 12, an 
initially missed node metastasis at Naruke 16 was detected on PET/CT fusion. Two 
other enlarged lymph nodes >1 cm at Naruke 8 and 17 did not show any FDG-
uptake on visual correlation. In patient 13, no nodal involvement was observed on 
PET scanning, but on PET/CT fusion there was indeed FDG- uptake in the para-
oesophageal lymph nodes.   
In one patient (patient 14), the number of metastases decreased. CT detected three 
lymph nodes > 1 cm, but on side-by-side fusion it was impossible to determine 
whether these nodes were involved due to their close proximity. PET/CT fusion 
clearly showed that one of these nodes did not absorb any FDG. Unfortunately, at 
exploration, pathologically proven cervical metastasis was found and resection was 
abandoned. Hence, PET/CT findings of enlarged lymph nodes at Naruke 8 were 
verified by the 12-months follow-up. 
 
Figure 1. Upstaging (a) and downstaging (b)                                              
 
a 
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(a) Patient 15: FDG-PET, low suspicion for both nodal and skeletal metastases, but without suspicion on md-CT or 
EUS. Software fusion clearly showed metastatic nodal metastasis in the para-oesophageal region. Magnification 
shows the involved lymph node. 
 
 
(b) Patient 16: enlarged lymph node in the paracardial region staged as N1 on md-CT. On FDG-PET, FDG-uptake was 
seen in the celiac region, staged as M1a. After software PET/CT fusion both findings appeared to be the same lesion in 
the paracardial region. 
 
Altered staging  
The TNM classification was altered by PET/CT fusion in 4 patients (patients 15 to 
18; 6.6%). Upstaging was found in one patient (15), but had no impact on the 
resectability. There was a low suspicion on PET for nodal (Naruke 8 and 20) and 
skeletal metastases, not confirmed by CT or EUS. After software PET/CT fusion 
pathologically confirmed metastatic lymph nodes were clearly visible at Naruke 8 
and 16 (Figure 1a). Downstaging by PET/CT fusion was found in three patients 
(patient 16, to 18). In patient 16 an enlarged node at Naruke 16 was staged as N1 on  
 
Table 4. Details of the 18 patients with differences in staging between software PET/CT 
fusion and visual correlation                                                                                                                                                          
Pt Lpt H S I LEUS (n) Lvisu(n) Lsoft (n) Lpath (n) 
1 Distal AC III 2 16, 17 (2) 16 (1) 16 (1) 7,8,16,17 
(22) 
2 GOJ AC III 2 - (0) 17 (1) 17 (1) 17 (3) 
3 Distal SC III 2 4/5,17 (5) 4/5,17 (10) 4/5,17 (12) 4/5, 20 (2) 
4 GOJ AC III 2 4/5,7,8,16, 7,8,16 (6) 7,8,16 (6) 8,16 (2) 
b 




5 Distal AC IVA
B 










7 Distal AC III 2 8 (1) 8 (1) 8 (1) 8,16 (2) 
8 Distal AC IVA 2 7, 18 (3) 8,17 (4) 8,17 (4) 8,17 (4) 
9 GOJ AC IVA 2 20 (3) 17,20 (3) 20 (3) 20 (2) 
10 Distal AC IIB 3 8 (1) 17 (1) 8,16,17 (3) 8,16,17 (3) 
11 Distal SC III 3 8 (1) 7 (1) 4/5,7 (2) 4/5,8 (8) 
12 GOJ AC III 3 16 (3) 19 (1) 19,16 (2) 16 (1) 
13 Distal AC III 3 8 (1) - (0) 8 (1) 4,5,8,16 
14 Distal AC III 4 8 (1) 8 (5) 8 (4) - 
15 Distal AC IIA 6 - (0)  - (0) 8, 16 (2) 8, 16, 17 
16 Distal AC IVA 8 16 (2) 16, 20 (2) 16 (1) 16, 17 (2) 
17 Distal AC IIA 8 - (0) 4/5, 7 (3)  - (0) - (0) 
18 Distal AC III 8 17 (3) 17, 20 (3) 17 (2) 8, 16, 17  
Lpt: location of primary tumour, GOJ: gastro-oesophageal junction, H: histology, AC: adenocarcinoma, SC: squamous 
cell carcinoma, S: clinical stage based on staging without PET/CT fusion, I: improvements 2-9: see Table II, L: 
localization of lymph node station(s) according to Naruke by endoscopic ultrasound (EUS), visual correlation (visu), 
software fusion (soft) or on pathological examination (path), 4/5:paratracheal, 8: para-oesophageal, 16: 
paracardial/curv. minor, 17: left gastric artery, 20: celiac trunk, n: number of lymph node metastases. 
 
CT, but as FDG-uptake was visible at the celiac trunk it was staged as M1a. At 
PET/CT fusion both findings appeared to be the same lesion, staged as N1 (Figure 
1b). In patient 17, three lymph nodes > 1 cm were found on CT and during visual 
correlation it was unclear whether a slightly diffuse accumulation of FDG-uptake 
was attributable to these nodes or to a Barrett oesophagus segment. PET/CT fusion 
showed undeniably that these nodes were clear. In patient 18, a suspicious celiac 
node metastasis (Naruke 20) was noted on visual correlated FDG-PET, but software 
PET/CT fusion enabled precise localization of increased FDG-uptake at Naruke 17. 
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Sensitivity, specificity and accuracy  
Although not statistically significant (p=0.250), the diagnostic accuracy of 
PET/CT fusion (87%; 53/61) was slightly better than side-by-side visualization 
(82%; 50/61) in the assessment of locoregional metastases. Sensitivity and 
specificity of side-by-side visualization were 80% (12/15) and 83% (38/46), 
respectively. The sensitivity and specificity of PET/CT fusion in the assessment 
of nodal metastases were both 87%; 13/15 and 40/46, respectively. 




This study showed that software-fused PET/CT had a supplementary value over 
visually correlated FDG-PET and md-CT in the assessment of nodal metastases in 
30% of the patients with cancer of the oesophagus. Improved assessment of 
locoregional tumour foci is necessary for appropriate surgical treatment, but also for  
more accurately planned target volumes, particularly in the neoadjuvant 
chemoradiation treatment of these tumours.29,30 Refinement of the nodal assessment 
was found by PET/CT fusion compared to the side-by-side visualisation method, 
even though the N-stage itself was not significantly affected. It is this refinement 
that is of major importance in radiotherapy planning. 
However, there are some potential pitfalls in the interpretation of PET/CT fusion 
images. Although md-CT has a high accuracy in detecting enlarged lymph nodes, its 
specificity for metastases is low. Previous studies showed that lymph nodes of > 1 
cm on CT without FDG-uptake on PET are usually benign.23,31,32 Visual correlation 
between PET and CT is usually sufficient to determine this difference. Therefore, 
improvements in staging were not taken into account when summarizing 
improvements of software fusion compared to visual fusion. This statement should 
be interpreted with caution as it was difficult to visualize the regional lymph nodes 
near the primary tumour. In many cases, FDG-uptake in the primary tumour may 
mask nearby lesions, due to the assimilation of FDG-uptake in both. The para-
oesophageal and paracardial areas are particularly difficult to interpret in this way. 
The lymph nodes can be categorized only as benign on the aforementioned criteria 
when they are not in the proximity of the primary tumour. Software fusion can be 
helpful in identifying whether these lymph nodes are located near the primary 
tumour. Another pitfall in the determination of nodal metastases on PET/CT fusion 
is the difficulty in exact pathological localization. Only meticulous marking during 
surgery with mapping of all visible or palpable nodes region by region in the 
resected specimen according to the Japanese method makes correct identification 
possible. 
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There are also some inherent difficulties in software PET/CT fusion. Firstly, the 
outlining in software fusion depends, to a certain extent, on human expertise and 
appraisal, as does its evaluation. Therefore, small inter-observer variation is 
inherent to this kind of science.31 To overcome this problem in the present study, all 
the fusion images were studied and scored separately by an experienced nuclear 
physician and a radiologist. Disagreements were solved in a consensus meeting. 
Secondly, the software-fused images consist of two images from two different 
techniques at different times. Consequently body posture and position differ 
between the md-CT and PET. Fortunately, structures close to the spine, like the 
oesophagus, show only minimal movements and are therefore very suitable for 
fusion, though the position of the diaphragm often does not match as md-CT is 
conducted at maximum inspiration and PET during moderate respiration. 
Therefore, it is difficult to fuse PET and CT images below the vault of the 
diaphragm. Some authors have reported a failure of 30-39% in software PET/CT 
fusion of the evaluated cases.32,33 However, these studies also described an increased 
success rate if the PET transmission data were incorporated in the fusion process for 
attenuation correction.             
Recently hybrid PET/CT scanners have become available. The use of hybrid 
scanners partly overcomes these above mentioned limitations because PET and md-
CT are performed simultaneously, in the same body posture and nearly at the same 
diaphragm position. Several studies comparing hybrid PET/CT with visually 
correlated FDG-PET/CT have reported an improvement of 22-49% in the detection, 
localization and characterization of malignant lesions with an accuracy of 90-96%.21-
23,34-36 Nevertheless, hybrid FDG-PET/CT scanners still consist of two separate 
scanners in one combined device, and difficulties may occur in the application of 
these scanners. The quality of the md-CT scan as part of a hybrid scan is frequently 
inferior to the quality of a separate md-CT scan, because md-CT is primarily based 
on anatomical mapping for precise localization of structures for FDG-PET. 
Additionally, oral contrast fluid is not administered, accurate imaging of pulmonary 
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and hepatic lesions might be problematic due to respiratory movements and timing 
for arterial/venous imaging are not optimal. Furthermore, as earlier research has 
revealed no benefit of FDG-PET in stage I and II disease, hybrid scanning seems to 
be of limited value compared to md-CT in this group of patients.37 It is a relatively 
expensive investigation used in a whole population, while PET scanning will have 
no additional value in some subgroups.    
In conclusion, fusion of FDG-PET and md-CT images improves the detection and/or 
localization of locoregional metastases in oesophageal cancer cases with a more 
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